Q1 2021 Calliditas Therapeutics AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Calliditas Therapeutics Q1 2021 Conference. (Operator Instructions)
I'll now hand the floor to CEO, Renee Lucander. Please begin your meeting.
()-
Thank you, and welcome to this Q1 2021 report from Calliditas. If you turn to Page 2, and before we begin, giving our listing on NASDAQ Global Select, I would just like to draw your attention to the forward-looking statements.
So turning to Page 3. In Q1, the company reached a major milestone with a filing for approval in IgA nephropathy with the FDA. This is the first-ever submission for proven IgAN, and it provides for thousands of patients living every day with this progressive disease. We subsequently received priority review from the FDA, and we're also granted accelerated assessment by EMA in April.
We continue to deliver on our plan, and we will submit our dossier to EMA this quarter, as previously announced, and we're very excited to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
